Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Bank of America

Bank of America upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from an underperform rating to a buy rating in a report issued on Wednesday morning, MarketBeat Ratings reports. The brokerage currently has $860.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $627.00.

Several other equities research analysts have also recently issued reports on REGN. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. UBS Group boosted their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. HSBC assumed coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They set a “buy” rating and a $255.00 price target on the stock. Finally, Truist Financial started coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They issued a “buy” rating and a $798.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $791.05.

Regeneron Pharmaceuticals Trading Down 0.6%

Shares of REGN opened at $796.55 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $821.11. The stock has a market cap of $83.72 billion, a price-to-earnings ratio of 19.07, a price-to-earnings-growth ratio of 2.17 and a beta of 0.39. The firm has a 50 day simple moving average of $738.12 and a 200-day simple moving average of $628.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the prior year, the firm earned $12.46 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up .9% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.4%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director owned 2,352 shares in the company, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 8,431 shares of company stock valued at $5,733,521. Company insiders own 7.02% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in REGN. Salomon & Ludwin LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $31,000. Board of the Pension Protection Fund purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. Caitlin John LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Finally, Traub Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $38,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Multiple analyst upgrades and higher targets — Bank of America and other firms raised ratings/targets this week, shifting consensus toward Buy and boosting investor confidence. Bank of America upgrade
• Positive Sentiment: Zacks moved REGN to a Zacks Rank #1 (Strong Buy), highlighting expectations for continued earnings outperformance. Zacks upgrade
• Positive Sentiment: Truist and other brokers raised price targets (Truist to $820), and aggregated analyst coverage (21‑analyst notes) points to a more favorable fundamental outlook — a catalyst for momentum buyers. 21‑analyst roundup
• Neutral Sentiment: Unusual options activity has picked up around REGN, signaling elevated trader interest and potential for amplified short‑term moves; direction is ambiguous. Unusual options activity
• Neutral Sentiment: Comparative analyst pieces (REGN vs peers) provide valuation context but are not immediate catalysts. REGN vs ILMN analysis
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at roughly $800 — a small dollar amount relative to market cap but sometimes triggers investor concern and short‑term profit‑taking. Insider sale SEC filing

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.